CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
Abstract Background Chimeric antigen receptor NK (CAR-NK) cell therapy is one of the most promising immunotherapies. Although it has shown a significant therapeutic effect in hematologic malignancies, few successes have been obtained in solid tumors including esophageal squamous cell carcinoma (ESCC...
Main Authors: | Tingdang Liu, Ximing Dai, Yien Xu, Tian Guan, Liangli Hong, Tahir Zaib, Qi Zhou, Ke Cheng, Xiaoling Zhou, Changchun Ma, Pingnan Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-023-04409-8 |
Similar Items
-
Immunotherapy of B cell lymphoma
with CD22-redirected CAR NK-92 cells
by: Xiaopeng Tian, et al.
Published: (2023-04-01) -
Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
by: Adrien Krug, et al.
Published: (2021-12-01) -
Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma
by: Xiaolan Lin, et al.
Published: (2024-03-01) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
by: Sergey Kulemzin, et al.
Published: (2021-11-01) -
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
by: Xinyu Wu, et al.
Published: (2022-12-01)